Enanta Pharmaceuticals Inc. reported an impressive 96 percent sustained virologic response after 12 weeks of treatment (SVR12) for hepatitis C virus (HCV) in its Phase III (SAPPHIREII) study of a regimen containing protease inhibitor ABT-450 (ritonavir).